We are a clinical stage biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.
We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.
We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.
Oct 13, 2019 10:56 PM EDT
Copyright West LLC. Minimum 15 minutes delayed.
News and Events
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASHRead more
NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASHRead more
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®Read more
More events are coming soon.